Accelerate Diagnostics Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 0/6

Accelerate Diagnostics har ett totalt eget kapital på $-48.5M och en total skuld på $58.0M vilket ger sin skuldsättningsgrad till -119.6%. Dess totala tillgångar och totala skulder är $32.3M respektive $80.8M.

Viktig information

-119.6%

Skuldsättning i förhållande till eget kapital

US$58.01m

Skuld

Räntetäckningsgrad	n/a
Kontanter	US$20.91m
Eget kapital	-US$48.48m
Summa skulder	US$80.80m
Totala tillgångar	US$32.32m

Nya uppdateringar om finansiell hälsa

Recent updates

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Apr 17

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Aug 30

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Aug 20

Accelerate Diagnostics jumps 14% after beating Q2 estimates

Aug 15

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Mar 15

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Jan 04

Accelerate Diagnostics: An Investment Assessment

Sep 07

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Feb 20

Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus

Jan 12

Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

Dec 29

Analys av finansiell ställning

Kortfristiga skulder: AXDX har negativt eget kapital, vilket är en allvarligare situation än kortfristiga tillgångar som inte täcker kortfristiga skulder.

Långfristiga skulder: AXDX har negativt eget kapital, vilket är en allvarligare situation än kortfristiga tillgångar som inte täcker långfristiga skulder.

Skuld till eget kapital Historik och analys

Skuldnivå: AXDX har negativt eget kapital, vilket är en allvarligare situation än en hög skuldnivå.

Minska skulden: AXDX s har negativt eget kapital, så vi behöver inte kontrollera om dess skulder har minskat över tiden.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: AXDX har mindre än ett år av cash runway baserat på dess nuvarande fria kassaflöde.

Prognos Cash Runway: AXDX har mindre än ett år av kontanter om det fria kassaflödet fortsätter att växa i historiska takter på 11.2 % varje år.

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/04 01:19
Aktiekurs vid dagens slut	2025/03/04 00:00
Intäkter	2024/09/30
Årlig intjäning	2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Accelerate Diagnostics, Inc. bevakas av 6 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Sean Lavin	BTIG
Garrett Nelson	CFRA Equity Research
Alexander Nowak	Craig-Hallum Capital Group LLC

Accelerate Diagnostics Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 0/6

Viktig information

Nya uppdateringar om finansiell hälsa

Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS Requirement

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS Requirement

Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System

Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial

Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq

Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024

Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC

Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust

Accelerate Diagnostics, Inc. has completed a Composite Units Offering.

Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CEO, President & Director exercised options and sold US$73k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit

Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer

Consensus forecasts updated

Price target decreased to US$2.00

Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022

Insider recently bought US$80k worth of stock

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Consensus revenue estimates increase by 10%

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Accelerate Diagnostics jumps 14% after beating Q2 estimates

CEO, President & Director exercised options and sold US$26k worth of stock

Consensus forecasts updated

Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA

First quarter 2022 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$82k worth of stock

Price target decreased to US$5.00

Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022

Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Consensus revenue estimates fall by 14%

Full year 2021 earnings: EPS exceeds analyst expectations

Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board

Insider recently bought US$66k worth of stock

Independent Director recently bought US$524k worth of stock

Independent Director recently bought US$196k worth of stock

Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Independent Director recently bought US$277k worth of stock

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Independent Director recently bought US$369k worth of stock

Independent Director recently bought US$248k worth of stock

Independent Director recently bought US$606k worth of stock

Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)

Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding

Independent Director recently bought US$150k worth of stock

Price target decreased to US$11.00

Accelerate Diagnostics: An Investment Assessment

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Accelerate Diagnostics, Inc. to present New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits at ECCMID 2021

CEO, President & Director exercised options and sold US$186k worth of stock

Key Executive exercised options and sold US$56k worth of stock

Price target decreased to US$11.00

First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020)

Accelerate Diagnostics, Inc. Announces Roland D. Diggelmann Decision Not to Stand for Re-Election to Its Board

Analysts lower revenue estimates to US$16.5m

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?